Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: Influence of ATS/ERS/IASLC guidelines

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 69-75

  Ferretti, Gilbert R ^a   Busser, Benoit ^b   de Fraipont, Florence ^b   Reymond, Emilie ^a   McLeer Florin, Anne ^b   Mescam Mancini, Lena ^b   Moro Sibilot, Denis ^a   Brambilla, Elisabeth ^b   Lantuejoul, Sylvie ^b  

^a INSTITUT ALBERT BONNIOT   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

ALK; EGFR; Histology; KRAS; Lung adenocarcinoma; Transthoracic needle core biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYROSEQUENCING; TISSUE SECTION; TRANSTHORACIC BIOPSY;

ALK; ANAPLASTIC LYMPHOMA KINASE; CHROMOGENIC IN SITU HYBRIDIZATION; CISH; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; FINE NEEDLE ASPIRATION; FISH; FLUORESCENT IN SITU HYBRIDIZATION; FNA; HISTOLOGY; KRAS; LUNG ADENOCARCINOMA; TKI; TRANS-THORACIC NEEDLE CORE BIOPSY; TRANSTHORACIC NEEDLE CORE BIOPSY; TTNB; TYROSINE KINASE INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMAGE-GUIDED BIOPSY; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884418250     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.010     Document Type: Article

References (36)

1. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
2. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
4. Arcila M.E., Oxnard G.R., Nafa K., Riely G.J., Solomon S.B., Zakowski M.F., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17(5):1169-1180.
5. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
6. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6(9):1496-1504.
7. Bryant C.M., Albertus D.L., Kim S., Chen G., Brambilla C., Guedj M., et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS ONE 2010, 5(7):e11712.
8. Wiener R.S., Schwartz L.M., Woloshin S., Welch H.G. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011, 155(3):137-144.
9. Solomon S.B., Zakowski M.F., Pao W., Thornton R.H., Ladanyi M., Kris M.G., et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010, 194(1):266-269.
10. Chen C.M., Chang J.W., Cheung Y.C., Lin G., Hsieh J.J., Hsu T., et al. Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer. Acta Radiol 2008, 49(9):991-994.
11. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., Ceccaldi F., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7(2):348-354.
12. Dufort S., Richard M.J., de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009, 391(2):166-168.
13. Dufort S., Richard M.J., Lantuejoul S., de Fraipont F. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011, 30:57.
14. Laurent F., Latrabe V., Vergier B., Michel P. Percutaneous CT-guided biopsy of the lung: comparison between aspiration and automated cutting needles using a coaxial technique. Cardiovasc Intervent Radiol 2000, 23(4):266-272.
15. Klein J.S., Salomon G., Stewart E.A. Transthoracic needle biopsy with a coaxially placed 20-gauge automated cutting needle: results in 122 patients. Radiology 1996, 198(3):715-720.
16. Yeow K.M., Su I.H., Pan K.T., Tsay P.K., Lui K.W., Cheung Y.C., et al. Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest 2004, 126(3):748-754.
17. Ghaye B., Dondelinger R.F. Imaging guided thoracic interventions. Eur Respir J 2001, 17(3):507-528.
18. Cheung Y.C., Chang J.W., Hsieh J.J., Lin G., Tsai Y.H. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer 2010, 67(2):166-169.
19. Shah P.L., Singh S., Bower M., Livni N., Padley S., Nicholson A.G. The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer. J Thorac Oncol 2006, 1(4):324-327.
20. Meert A.P., Martin B., Verdebout J.M., Paesmans M., Berghmans T., Ninane V., et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004, 44(3):295-301.
21. Sigel C.S., Moreira A.L., Travis W.D., Zakowski M.F., Thornton R.H., Riely G.J., et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011, 6(11):1849-1856.
22. Hasanovic A., Rekhtman N., Sigel C.S., Moreira A.L. Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Pathol Res Int 2011, 2011:897292.
23. Pelosi G., Rossi G., Bianchi F., Maisonneuve P., Galetta D., Sonzogni A., et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011, 6(6):1039-1049.
24. Rekhtman N., Brandt S.M., Sigel C.S., Friedlander M.A., Riely G.J., Travis W.D., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6(3):451-458.
25. Nicholson A.G., Gonzalez D., Shah P., Pynegar M.J., Deshmukh M., Rice A., et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010, 5(4):436-441.
26. Rossi G., Papotti M., Barbareschi M., Graziano P., Pelosi G. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 2009, 27(28):e141-e142. [author reply e143-144].
27. Aviram G., Greif J., Man A., Schwarz Y., Marmor S., Graif M., et al. Diagnosis of intrathoracic lesions: are sequential fine-needle aspiration (FNA) and core needle biopsy (CNB) combined better than either investigation alone?. Clin Radiol 2007, 62(3):221-226.
28. Yamagami T., Iida S., Kato T., Tanaka O., Nishimura T. Combining fine-needle aspiration and core biopsy under CT fluoroscopy guidance: a better way to treat patients with lung nodules?. AJR Am J Roentgenol 2003, 180(3):811-815.
29. Bocking A., Klose K.C., Kyll H.J., Hauptmann S. Cytologic versus histologic evaluation of needle biopsy of the lung, hilum and mediastinum. Sensitivity, specificity and typing accuracy. Acta Cytol 1995, 39(3):463-471.
30. Schreiber G., McCrory D.C. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003, 123(1 Suppl.):115S-128S.
31. Boldrini L., Gisfredi S., Ursino S., Camacci T., Baldini E., Melfi F., et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007, 2(12):1086-1090.
32. Horiike A., Kimura H., Nishio K., Ohyanagi F., Satoh Y., Okumura S., et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007, 131(6):1628-1634.
33. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009, 117(1):67-72.
34. Billah S., Stewart J., Staerkel G., Chen S., Gong Y., Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011, 119(2):111-117.
35. Kim E.S., Herbst R.S., Wistuba I.I., Lee J.J., Blumenschein G.R., Tsao A., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1(1):44-53.
36. Li T., Kung H.J., Mack P.C., Gandara D.R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013, 31(8):1039-1049.